



HEALTHY LIVING OPPORTUNITIES NEWSLETTER



MARKETING COMMUNICATION | FOR PROFESSIONAL CLIENTS ONLY | MAY 2026

THIS DOCUMENT HAS BEEN PREPARED FOR DISCUSSION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OR A SOLICITATION TO ENGAGE IN ANY TRADING STRATEGY OR THE PURCHASE OR SALES OF ANY FINANCIAL INSTRUMENT.

INVESTMENT OBJECTIVE

The objective of the fund is to increase the value of its assets over the medium term by being exposed to a dynamic basket of equities listed on worldwide markets, whose activities are linked to the "Healthy Living" theme, meeting environmental, social and governance criteria (ESG) and complying with financial filters.

STRATEGY

Investing in Healthy Living with BNP Paribas Exane's dynamic approach:

- **Investment universe:** World coverage of liquid companies, divided in three main regions: Europe, North America and Asia (~800 stocks) paired with ESG exclusions (disputable activities, UN Global Compact, controversies).
- **Healthy Living Scoring:**
 - In-house Artificial Intelligence model used for large-scale scanning of companies' activities
 - Analysis of company revenues generated from each industry segment
 - Systematic and analyst-based relevance controls of selected companies to determine final scoring.
- **Financial filters:** Exclusion of companies with the weakest financial perspectives.
- **Portfolio Construction:** Selects companies that maximise the portfolio's Healthy Living Score, taking into account Sustainable Investments requirement and diversification constraints.

These internal guidelines are for indicative purposes only; Prospectus and KID are prevailing.


PERFORMANCE

As of May 29th, 2026

Sep 24 - May 26	THEAM Quant- Healthy Living Opportunities	MSCI World Net Total Return USD Index
Performance 1 month	4.38%	4.55%
Cumulative Performance Year To Date	-5.35%	10.49%
Annualised Performance Since Start Date	-2.89%	19.05%
Annualised Volatility Since Start Date	15.05%	13.81%
Max Drawdown Since Start Date	-16.87%	-16.56%


Source: Bloomberg. Past performance is not an indicator of future performance.

Follow the icon to go to the fund page on the THEAM Quant website



Learn more ABOUT GLOBAL MARKETS

<https://globalmarkets.cib.bnpparibas/>



MACRO BACKGROUND

Our fund posted a positive return in May: 4.38%. The fund underperformed the MSCI World index (by -0.17%) over this month.

PERFORMANCE BREAKDOWN

The strategy delivered a 4.5% performance with notable contributions from Illumina (performance: 28.6% / key segment: Diagnostics & Cure), Dexcom (performance: 23.8% / key segment: Diagnostics & Cure), and Life Time Group Holdings (performance: 23.4% / key segment: Active lifestyle).

On the negative side, Planet Fitness (-19.7%) and Boston Scientific (-16.1%) weighted on the month's performance.



From a sector perspective, Healthcare (contributing 2.6%), Consumer Non-Cyclicals (contributing 0.9%) and Cyclical Consumer Goods & Services (contributing 0.8%) were the primary contributors, while Financials (0%) and Basic Materials (0.3%) provided the weakest contributions.

HIGHLIGHTS


On the wearable space, WHOOP has recently identified a new competitor that resembles it: the Fitbit Air launched by Google. While it adopts the same screenless fitness tacker design, it reverses the business model by charging customers for the device – WHOOP primarily relies on a subscription – and offers an optional subscription that unlocks additional features.

If we stay within Google's scope, the company held its Google I/O event in May ; two smartglasses models will be launched this fall. According to our analyst, the keynote omitted key details – weight, battery life and pricing – so we cannot rule out that the news may modestly support EssilorLuxottica's shares (among our strategy's constituents) which have been pressured by smartglasses competition since December 2025.

Insilico Medecine and Human Life Foundation Models (HLFM) have signed a multi-million-dollar partnership to build the first large-scale AI foundation model for human longevity, combining Insilico's generative AI expertise with HLFM's extensive de-identified multiomic and clinical data to accelerate disease risk prediction and therapeutic targets.




SECTOR RELATIVE WEIGHTS AND PERFORMANCE ATTRIBUTION





Source: BNP Paribas. Past performance is not an indicator of future performance

GEOGRAPHY RELATIVE WEIGHTS AND PERFORMANCE ATTRIBUTION



Source: BNP Paribas. Past performance is not an indicator of future performance



ESG REPORT

For the latest ESG Report of the THEAM Quant – Healthy Living Opportunities fund, please click the banner below.



CONTACTS

EQUITIES STRATEGIES, GLOBAL MARKETS | QIS Equities | dl.gmstructuringqisequities@bnpparibas.com
BNP PARIBAS ASSET MANAGEMENT | CIB Strategies Sales Support | LIST.AMGPECIBSALESSUPPORT@bnpparibas.com
dl.theam_gm_coordination@uk.bnpparibas.com

FUND CHARACTERISTICS AND RISKS

Fund	THEAM QUANT- HEALTHY LIVING OPPORTUNITIES					Capital protection	No
Management Company	BNP PARIBAS ASSET MANAGEMENT Europe					Minimum Investment horizon	5
Comparative Index	MSCI World (USD) NR					Legal form	SICAV
Assets under Management	USD 41.9 million as of 29 May 2026					SRI Ranking (scale from 1 to 7)*	4
SFDR article	This product promotes environmental or social characteristics pursuant to article 8 of the EU regulation 2019/2088.						
Share	I ACC	C EUR ACC	J ACC	X EUR ACC	C ACC		
Launch date	30 September 2024	30 September 2024	30 September 2024	30 September 2024	30 September 2024		
ISIN code	LU2654775001	LU2654775779	LU2654773725	LU2866522712	LU2654775936		
Bloomberg code	TEMLVI LX	TEMLVC LX	TEMLJC LX	TEMLVX LX	TEMLOCC LX		
Ongoing charges	0.66%	1.51%	0.42%	0.22%	1.51%		
Subscription / Exit fees	None / None	3.00% / None	None / None	None / None	3.00% / None		
Passporting	Greece, Switzerland, Germany, France, Cyprus, Luxembourg, Italy, Belgium	Switzerland, Greece, France, Italy, Luxembourg, Belgium, Germany, Cyprus	Belgium, Germany, Luxembourg, Italy, Switzerland, France	Luxembourg, Switzerland	Germany, Switzerland, Greece, France, Belgium, Luxembourg, Cyprus, Italy		

5 - The Summary Risk Indicator is determined on a scale from 1 to 7 (7 being the highest risk level), the higher the risk, the longer the recommended investment horizon.
 6 - For all shares available, please refer to the prospectus [here](#).

WHAT ARE THE RISKS?

The value of investments and the income from them may go down as well as up and investors may not get back the amount originally invested.

Liquidity Risk: This risk arises from the difficulty of selling an asset at a fair market price and at a desired time due to lack of buyers.

Counterparty Risk: Linked to the default of a counterparty on over-the-counter markets.

Risk related to the use of forward financial instruments: In order to achieve its investment objective, the UCITS makes use of forward financial instruments traded over-the-counter that allow it to replicate the performance of the strategy. These instruments may involve a series of risks that could lead to adjustments or even the early termination of the instrument, which may affect the net asset value of the UCITS.

For the full list of risks, please refer to the prospectus.

DISCLAIMER

“THEAM Quant” is the generic name given to a broad range of systematic strategies designed by BNP Paribas Global Markets and mostly implemented in Funds managed by BNP Paribas Asset Management

Legal Notice: This document is CONFIDENTIAL AND FOR DISCUSSION PURPOSES ONLY; it constitutes a marketing communication and has been prepared by a Sales and Marketing function within BNP Paribas and/or its subsidiaries or affiliates (collectively “we” or “BNP Paribas”). As a confidential document it is submitted to selected recipients only and it may not be made available (in whole or in part) to any other person without BNP Paribas’ written consent.

This document is not a recommendation to engage in any action, does not constitute or form any part of any offer to sell or issue and is not a solicitation of any offer to purchase any financial instrument, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. To the extent that any transaction is subsequently entered into between the recipient and BNP Paribas, such transaction will be entered into upon such terms as may be agreed by the parties in the relevant documentation.

The information contained in this document has been obtained from sources believed to be reliable, but there is no guarantee of the accuracy, completeness or suitability for any particular purpose of such information or that such information has been independently verified by BNP Paribas or by any person. None of BNP Paribas, its members, directors, officers, agents or employees accepts any responsibility or liability whatsoever or makes any representation or warranty, express or implied, as to the accuracy or completeness of the information, or any opinions based thereon, contained in this document and it should not be used in place of professional advice. Additional information may be provided on request, at our discretion. Any scenarios, assumptions, historical or simulated performances, indicative prices or examples of potential transactions or returns are included for illustrative purposes only. Past performance is not indicative of future results. Investors may get back less than they invested. BNP Paribas gives no assurance that any favourable scenarios described are likely to happen, that it is possible to trade on the terms described herein or that any potential returns illustrated can be achieved. This document is current as at the date of its production and BNP Paribas is under no obligation to update or keep current the information herein. In providing this document, BNP Paribas offers no investment, financial, legal, tax or any other type of advice to, and has no fiduciary duty towards, recipients. Certain strategies and/or potential transactions discussed in this document may involve the use of derivatives which may be complex in nature and may give rise to substantial risks, including the risk of total or partial loss of any investment or losses without limitation and which should only be undertaken by those with the requisite knowledge and experience. BNP Paribas makes no representation and gives no warranty as to the results to be obtained from any investment, strategy or transaction, or as to whether any strategy, security or transaction described herein may be suitable for recipients’ financial needs, circumstances or requirements. Recipients must make their own assessment of strategies, securities and/or potential transactions detailed herein, using such professional advisors as they deem appropriate. BNP Paribas accepts no liability for any direct or consequential losses arising from any action taken in connection with or reliance on the information contained in this document even where advised of the possibility of such losses.

As an investment bank with a wide range of activities BNP Paribas may face conflicts of interest and you should be aware that BNP Paribas and/or any of its affiliates may be long or short, for their own account or as agent, in investments, transactions or strategies referred to in this document or related products before the material is published to clients and that it may engage in transactions in a manner inconsistent with the views expressed in this document, either for their own account or for the account of their clients. Additionally, BNP Paribas may have acted as an investment banker or may have provided significant advice or investment services to companies or in relation to investments mentioned in this document. The information in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction where (a) the distribution or use of such information would be contrary to law or regulations, or (b) BNP Paribas or a BNP Paribas affiliate would become subject to new or additional legal or regulatory requirements. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly.

This document is intended for, and is directed at, (a) Professional Clients and Eligible Counterparties as defined by the European Union Markets in Financial Instruments Directive (“MiFID”), and (b) where relevant, persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and at other persons to whom it may lawfully be communicated (together “Relevant Persons”). Any investment or investment activity to which this document relates is available only to and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or its content.

This document is being communicated by BNP Paribas, a Limited Liability company incorporated in France. Registered Office: 16 boulevard des Italiens, 75009 Paris, France. 662 042 449 RCS Paris. BNP Paribas is lead supervised by the European Central Bank (ECB) and the French Autorité de Contrôle Prudentiel et de Résolution (ACPR). © BNP Paribas. All rights reserved.

For funds authorized for marketing in Switzerland or from Switzerland, prospectuses, key investor information documents, articles of association, annual or semi-annual reports can be obtained free of charge from the representative agent in Switzerland, BNP Paribas (Suisse) SA, 2, place de Hollande, CH-1204 Genève; Payment Agency services are provided by BNP Paribas Securities Services, Paris, Zurich branch, 16, Selnaustrasse, 8002 Zurich, Switzerland.

All information referred to in the present document is available at www.bnpparibas-am.com

